Trials / Completed
CompletedNCT00861601
Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eltrombopag 12.5 milligrams (mg) tablet | eltrombopag 12.5 mg tablet once a day |
| DRUG | eltrombopag 25 mg tablet | eltrombopag 25 mg tablet once a day |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-03-13
- Last updated
- 2015-05-12
- Results posted
- 2010-09-23
Locations
10 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00861601. Inclusion in this directory is not an endorsement.